JP2015512418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512418A5 JP2015512418A5 JP2015503627A JP2015503627A JP2015512418A5 JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5 JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5
- Authority
- JP
- Japan
- Prior art keywords
- scopolamine
- ketamine
- disorder
- medicament according
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 42
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 42
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 42
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 42
- 229960003299 ketamine Drugs 0.000 claims description 42
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 42
- 229960002646 scopolamine Drugs 0.000 claims description 42
- 230000037396 body weight Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618212P | 2012-03-30 | 2012-03-30 | |
| US61/618,212 | 2012-03-30 | ||
| PCT/US2013/034524 WO2013149102A1 (en) | 2012-03-30 | 2013-03-29 | Compositions comprising scopolamine and ketamine in the treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Division JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512418A JP2015512418A (ja) | 2015-04-27 |
| JP2015512418A5 true JP2015512418A5 (enExample) | 2015-06-11 |
Family
ID=49261273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503627A Pending JP2015512418A (ja) | 2012-03-30 | 2013-03-29 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150057306A1 (enExample) |
| EP (1) | EP2830604A4 (enExample) |
| JP (2) | JP2015512418A (enExample) |
| WO (1) | WO2013149102A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| CA2922507C (en) * | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| CN111630026A (zh) | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| EP3710079A4 (en) * | 2017-11-14 | 2021-09-01 | Bexson Biomedical, Inc. | SYSTEMS, DEVICES, FORMULATIONS AND PROCEDURES FOR CONTROLLED INGREDIENT DELIVERY |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| EP3829539A4 (en) * | 2018-08-02 | 2022-05-04 | Taiwan Liposome Company, Ltd. | DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF |
| JP2022524008A (ja) | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| EP3968979A4 (en) | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
| EP4041209A4 (en) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| WO2022011170A1 (en) * | 2020-07-09 | 2022-01-13 | Light Aqua Llc | Compositions and methods for treating mood disorders and circadian rhythm sleep disorders |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| US20240050502A1 (en) * | 2020-12-16 | 2024-02-15 | Caamtech, Inc. | Amanita muscaria compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060646C (zh) * | 1993-06-07 | 2001-01-17 | 李举寿 | 戒毒注射液及其制造方法 |
| US8859585B2 (en) * | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
-
2013
- 2013-03-29 EP EP13767616.9A patent/EP2830604A4/en not_active Withdrawn
- 2013-03-29 JP JP2015503627A patent/JP2015512418A/ja active Pending
- 2013-03-29 US US14/388,410 patent/US20150057306A1/en not_active Abandoned
- 2013-03-29 WO PCT/US2013/034524 patent/WO2013149102A1/en not_active Ceased
-
2016
- 2016-03-17 US US15/072,970 patent/US20170042878A1/en not_active Abandoned
-
2018
- 2018-07-20 JP JP2018136350A patent/JP2018184440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512418A5 (enExample) | ||
| NZ604029A (en) | Methods of treating bladder cancer | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2014528901A5 (enExample) | ||
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| JP2012041342A5 (enExample) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| Gliedt et al. | Narrative review of perioperative acupuncture for clinicians | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| JP2011518787A5 (enExample) | ||
| TN2015000480A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2017061488A5 (enExample) | ||
| JP2017524721A5 (enExample) | ||
| HK1222585A1 (zh) | 用於提供疼痛减轻和麻醉的二氢埃托啡 | |
| MX2010006724A (es) | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| JP2010538054A5 (enExample) | ||
| JP2016504361A5 (enExample) | ||
| JP2015512923A5 (enExample) | ||
| JP2015508052A5 (enExample) | ||
| BR112016015281A8 (pt) | uso de um filtro em linha intravenoso, e método para preparação de um conjunto de infusão | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности |